EP4015504A1 — C5ar antagonists
Assigned to Chemocentryx Inc · Expires 2022-06-22 · 4y expired
What this patent protects
A process for preparing a compound of formula (ii),(2R, 3S) comprising(a) treating a compound of formula (i) with H<sub>2</sub> and a platinum oxide catalyst under reducing conditions; and(b) subjecting the product of step (a) to resolution with di-toluoyl-L-tartaric …
USPTO Abstract
A process for preparing a compound of formula (ii),(2R, 3S) comprising(a) treating a compound of formula (i) with H<sub>2</sub> and a platinum oxide catalyst under reducing conditions; and(b) subjecting the product of step (a) to resolution with di-toluoyl-L-tartaric acid to provide compound (ii) in about 97% enantiomeric excess.
Drugs covered by this patent
- Tavneos (AVACOPAN) · Chemocentryx
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.